Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study.
Irene DogliottiVeronica PeriMichele ClericoFrancesco VassalloDavide MustoSilvio MercadanteSimone RagainiBarbara BottoMario LevisMattia NovoMarco GhislieriLuca MolinaroUmberto MortaraChiara ConsoliAlessio LonardoGiulia BondielliSimone FerreroRoberto FreiloneUmberto RicardiBenedetto BrunoFederica CavalloPublished in: Cancer medicine (2024)
Our findings confirm very poor outcomes of R/R DLBCL in the rituximab era. Widespread approval by national Medicine Agencies of novel treatments such as CAR-T cells and bispecific antibodies as second-line is eagerly awaited to improve these outcomes.